Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19(T2)28z1xx CAR T cells in Relapsed or Refractory B-cell Malignancies
NCT04464200Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2020
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 19(T2)28z-1XX CAR T cells in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), chronic lymphocytic leukemia (CLL) and 5 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Recommended Phase II Dose at 28 days. Started Jul 2020; status: active, not recruiting.
02
Drugs
19(T2)28z-1XX CAR T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)chronic lymphocytic leukemia (CLL)Indolent Non-Hodgkin Lymphoma (INHL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04464200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464200.